Starting July 2026, Medicare Created a New Path to $50 GLP-1 Medications

For years, one of the biggest barriers to GLP-1 medications has been cost. Many Medicare beneficiaries who could benefit from these medications for weight management simply haven’t been able to afford them. CMS is attempting to remove this barrier, even if only temporarily.

Beginning July 1, 2026, CMS launched the Medicare GLP-1 Bridge, a short-term demonstration program that gives eligible Medicare Part D beneficiaries access to certain GLP-1 medications for a fixed copay of $50 per month. If your practice cares for Medicare patients struggling with obesity or weight-related conditions, this is a program worth understanding.

What Exactly Is the Medicare GLP-1 Bridge?

The easiest way to think about the Medicare GLP-1 Bridge is it is not a new Medicare benefit. Instead, it is a temporary CMS program designed to “bridge” access to certain GLP-1 medications for patients who otherwise would not receive coverage through their Medicare Part D plan.

The program provides access from July 1, 2026, and through December 31, 2027.

During that time, CMS will evaluate whether expanding access to GLP-1 medications improves health outcomes, affects Medicare spending, and influences future coverage decisions.

Why Didn’t CMS Simply Add These Drugs to Medicare?

CMS chose to launch a demonstration program outside of the traditional Part D payment system rather than expanding the Part D benefit.

This allows CMS to evaluate:

• utilization patterns
• patient outcomes
• prescribing trends
• program costs
• operational challenges

Because this program operates outside of Medicare Part D, CMS, not the patient’s Part D plan, manages eligibility, prior authorization, claims processing, and pharmacy reimbursement.

Impact On Your Practice

Many Medicare patients have asked about medications such as Wegovy® and Zepbound® but were unable to obtain coverage for weight management.

Now, many of those same patients may qualify through the Medicare GLP-1 Bridge.

The good news is that this process isn’t dramatically different from other medication prior authorization workflows, but there are several important differences that can prevent delays if your staff knows what to expect.

Before You Write the Prescription

This is where preparation becomes important.

The Medicare GLP-1 Bridge introduces its own eligibility requirements, prior authorization process, and documentation expectations. While the program creates a new pathway for patients, it also creates a new workflow for physician offices.

Understanding those requirements before the first prescription is written can help your staff avoid unnecessary denials, reduce delays at the pharmacy, and ensure documentation supports the information you’ll ultimately attest to during the prior authorization process.

Let’s walk through what your practice needs to know.

Who Is the Program Intended For?

The Medicare GLP-1 Bridge is not designed for every Medicare beneficiary. Instead, it was created for a specific group of patients who are seeking GLP-1 medications for weight management but who do not already qualify for coverage under the traditional Medicare Part D benefit.

For example, patients receiving a GLP-1 medication to treat Type 2 diabetes, moderate-to-severe obstructive sleep apnea, or metabolic dysfunction-associated steatohepatitis (MASH) should continue receiving those medications through their Medicare Part D plan, if eligible. Those patients are not candidates for the Bridge program.

The Bridge is intended to fill a different gap, providing a temporary pathway for eligible beneficiaries whose primary indication is weight reduction and maintenance.

CMS has established specific clinical criteria that providers must attest are met before coverage is approved.

These criteria are based on the patient’s:

• Age
• Body mass index (BMI)
• In some cases, the presence of qualifying medical conditions such as heart failure with preserved ejection fraction, chronic kidney disease, uncontrolled hypertension, previous myocardial infarction, previous stroke, peripheral artery disease, or pre-diabetes

What Does This Mean for Your Practice?

The good news is that your practice does not need to learn an entirely new prescribing process. The prescription is still written and transmitted to the patient’s pharmacy using your normal workflow.

What changes is how the prescription ultimately reaches coverage.

Because the Medicare GLP-1 Bridge operates outside of Medicare Part D, CMS uses a centralized system to determine patient eligibility, manage prior authorization, process claims, and reimburse the pharmacy.

In other words, your office is not submitting a prior authorization to the patient’s Part D plan. Instead, the request is reviewed through the Medicare GLP-1 Bridge program itself.

The Workflow Looks a Little Different

Although the prescribing process begins the same way, there are several operational differences your clinical and administrative staff should understand.

Before prescribing one of the covered GLP-1 medications, consider verifying:

• The patient is enrolled in an eligible Medicare Part D plan
• The medication is being prescribed for weight management rather than an indication already covered under Medicare Part D
• The patient appears to meet the Bridge program’s clinical eligibility criteria

CMS also recommends including an obesity diagnosis code from the E66 category and adding the notation “SEND TO BRIDGE FOR WEIGHT MANAGEMENT” on the prescription. While this notation is not required, it helps pharmacies route the prescription correctly. Without it, the pharmacy may initially submit the claim to the patient’s Part D plan, creating unnecessary delays.

Once the pharmacy submits the prescription to the Medicare GLP-1 Bridge, CMS verifies eligibility and instructs the pharmacy to generate a prior authorization request for the prescribing provider. That request is then completed by the prescriber, who attests that the patient meets the program’s clinical requirements.

Documentation Becomes More Important Than Ever

One of the biggest compliance considerations is not the prior authorization itself, it’s the documentation supporting it.

CMS is relying on provider attestation that the patient satisfies the program’s eligibility requirements. That means the medical record should clearly support:

• The indication for weight management
• The patient’s qualifying BMI at the time GLP-1 therapy was initiated, even if treatment began before the patient enrolled in Medicare or before the Bridge program launched
• Any qualifying comorbid conditions used to establish eligibility
• Documentation that the medication is being used in conjunction with ongoing lifestyle modification, including nutrition and physical activity, as required by the program

Remember, the prior authorization is an attestation. The medical record should be able to support every statement made if questions arise later.

A Practical Tip for Practice Managers

If your practice expects significant interest in this program, now is the time to develop a consistent workflow.

Consider creating a simple eligibility checklist for nursing or prior authorization staff, identifying who will complete the Medicare GLP-1 Bridge paperwork, and reviewing documentation expectations with your prescribing providers before the first patient request arrives.

A standardized process will likely reduce delays, minimize duplicate work, and help ensure documentation consistently supports the information submitted to CMS.

One Final Compliance Consideration

Because providers are attesting that beneficiaries meet the program’s eligibility requirements, practices should approach these requests with the same level of diligence they apply to any federal payer certification.

While the Medicare GLP-1 Bridge does not create new documentation guidelines, it does place greater emphasis on the accuracy of the medical record supporting eligibility. Practices may also wish to review this new workflow with their compliance team and, if appropriate, discuss whether any questions regarding provider attestations should be addressed with their professional liability carrier or legal counsel.

The Medicare GLP-1 Bridge gives physician practices an opportunity to help eligible Medicare patients gain affordable access to certain GLP-1 medications for weight management at a predictable cost of $50 per month. While the program is temporary, it represents an important CMS demonstration that could influence future Medicare coverage decisions.

For practices, success will depend on more than simply writing the prescription. Understanding the eligibility criteria, documenting medical necessity, and establishing a reliable office workflow will help patients receive timely access while keeping your practice compliant with the program’s requirements.

At a Glance: Is Your Patient a Candidate?

Before prescribing a GLP-1 medication through the Medicare GLP-1 Bridge, ask these six questions:

• Is the patient enrolled in Medicare Part D?
  If No, they are not eligible for the Bridge program.
• Are you prescribing the GLP-1 specifically for weight management?
  The Bridge program is only for eligible weight management indications, not conditions already covered under Medicare Part D.
• Does the patient already receive GLP-1 coverage through Medicare Part D?
  If Yes, continue using the patient’s existing Part D benefit. They are generally not eligible for the Bridge program.
• Does the patient appear to meet the Medicare GLP-1 Bridge clinical criteria?
  Eligibility is based on BMI at the time GLP-1 therapy was initiated and, in some cases, qualifying comorbid conditions.
• Can your documentation support the patient’s eligibility?
  Your medical record should support the qualifying BMI, applicable diagnoses, and that the medication is being prescribed alongside ongoing lifestyle modification.
• Is your practice prepared for the Bridge prior authorization process?
  Coverage requires a provider attestation through the Medicare GLP-1 Bridge workflow before the medication can be dispensed.

If you answered “Yes” to each question, your patient may be a good candidate for the Medicare GLP-1 Bridge. The next step is to prescribe an eligible GLP-1 medication and follow the Medicare GLP-1 Bridge prior authorization process.

Contact Us